FGEN (FibroGen) Debt-to-Asset : 0.30 (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is FibroGen Debt-to-Asset?

FibroGen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $5.9 Mil. FibroGen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $73.5 Mil. FibroGen's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $264.4 Mil. FibroGen's debt to asset for the quarter that ended in Sep. 2024 was 0.30.

FibroGen Debt-to-Asset Historical Data

The historical data trend for FibroGen's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen Debt-to-Asset Chart

FibroGen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.06

0.05

0.13

0.15

0.36

FibroGen Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															0.33	0.36	0.41	0.50	0.30

Competitive Comparison of FibroGen's Debt-to-Asset

For the Biotechnology subindustry, FibroGen's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FibroGen's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FibroGen's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where FibroGen's Debt-to-Asset falls into.

FibroGen Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

FibroGen's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(14.077	+	138.471)	/	423.529
	=	0.36

FibroGen's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(5.851	+	73.486)	/	264.421
	=	0.30

FibroGen (NAS:FGEN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

FibroGen Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of FibroGen's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

FibroGen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (NAS:FGEN) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

FGEN:Mexico 0IL8:UK 1FG:Germany

Address

409 Illinois Street, San Francisco, CA, USA, 94158

Website

https://www.fibrogen.com

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

Executives

Thane Wettig	officer: Chief Commercial Officer	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Jeffrey William Henderson	director	7000 CARDINAL PLACE, DUBLIN OH 43017
Enrique A Conterno	director, officer: Chief Executive Officer	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Christine Chung	officer: SVP, China Operations	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Jeffrey L Edwards	director	2525 DUPONT DR, IRVINE CA 92612
Aoife Brennan	director	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Benjamin Cravatt	director	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Suzanne Blaug	director	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Maykin Ho	director	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
James A Schoeneck	director	C/O DEPOMED, INC., 1360 O'BRIEN DRIVE, MENLO PARK CA 94025
Mark Eisner	officer: Incoming Chief Medical Officer	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Juan Graham	officer: Chief Financial Officer	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Kearns Thomas F Jr	director	P O BOX 587, WARSAW IN 46581-0587
Pat Controneo	officer: VP, Finance and CFO	C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158
Kalevi Kurkijarvi	director	C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158